MX346961B - Formulaciones farmaceuticas que contienen corticosteroides para la administracion topica. - Google Patents
Formulaciones farmaceuticas que contienen corticosteroides para la administracion topica.Info
- Publication number
- MX346961B MX346961B MX2013005764A MX2013005764A MX346961B MX 346961 B MX346961 B MX 346961B MX 2013005764 A MX2013005764 A MX 2013005764A MX 2013005764 A MX2013005764 A MX 2013005764A MX 346961 B MX346961 B MX 346961B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulations
- topical administration
- formulations containing
- containing corticosteroids
- corticosteroid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La potencia de un corticosteroide tópico en una formulación farmacéutica se mantiene incluso cuando la concentración del corticosteroide se reduce sustancialmente proporcionando el corticosteroide en una formulación que contiene un componente de aceite líquido que incluye un éster del ácido dicarboxílico y/o un éster del ácido monocarboxílico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45833910P | 2010-11-22 | 2010-11-22 | |
PCT/US2011/059861 WO2012087443A1 (en) | 2010-11-22 | 2011-11-09 | Pharmaceutical formulations containing corticosteroids for topical administration |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013005764A MX2013005764A (es) | 2013-06-28 |
MX346961B true MX346961B (es) | 2017-04-06 |
Family
ID=46064916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013005764A MX346961B (es) | 2010-11-22 | 2011-11-09 | Formulaciones farmaceuticas que contienen corticosteroides para la administracion topica. |
Country Status (20)
Country | Link |
---|---|
US (3) | US8809307B2 (es) |
EP (2) | EP2643002B1 (es) |
JP (1) | JP6111007B2 (es) |
KR (2) | KR101967121B1 (es) |
CN (1) | CN103228281B (es) |
AU (1) | AU2011345240B2 (es) |
BR (1) | BR112013012476B1 (es) |
CA (2) | CA2817524C (es) |
ES (1) | ES2935814T3 (es) |
HR (1) | HRP20230032T1 (es) |
HU (1) | HUE061270T2 (es) |
IL (1) | IL226398B2 (es) |
LT (1) | LT2643002T (es) |
MX (1) | MX346961B (es) |
NZ (1) | NZ610659A (es) |
PL (1) | PL2643002T3 (es) |
PT (1) | PT2643002T (es) |
RU (1) | RU2568598C2 (es) |
SI (1) | SI2643002T1 (es) |
WO (1) | WO2012087443A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8809307B2 (en) * | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
CN103705441B (zh) * | 2012-10-08 | 2017-06-23 | 天津金耀集团有限公司 | 一种丙酸倍氯米松乳膏 |
CN103705440B (zh) * | 2012-10-08 | 2017-05-10 | 天津金耀集团有限公司 | 一种哈西奈德乳膏 |
US8962028B2 (en) | 2012-10-18 | 2015-02-24 | MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company | Topical steroid composition and method |
US10111956B2 (en) | 2013-06-03 | 2018-10-30 | Tolmar, Inc. | Corticosteroid compositions |
CN104095805B (zh) * | 2014-01-02 | 2016-08-24 | 江苏知原药业有限公司 | 地奈德乳膏及其制备方法 |
US20160184431A1 (en) * | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
MX2017015990A (es) | 2015-06-18 | 2018-11-09 | Valeant Pharmaceuticals North America | Composiciones topicas que comprenden un corticosteroide y un retinoide para tratar psoriasis. |
US20190133943A1 (en) * | 2015-06-18 | 2019-05-09 | Valeant Pharmaceuticals North America | Topical compositions and methods for treating skin diseases |
CN106474052B (zh) * | 2016-12-16 | 2019-10-25 | 重庆华邦制药有限公司 | 二丙酸阿氯米松乳膏及其制备方法 |
US11311482B2 (en) | 2017-05-12 | 2022-04-26 | Bausch Health Us, Llc | Topical compositions and methods for treating skin diseases |
US10653656B2 (en) | 2018-04-05 | 2020-05-19 | Bausch Health Ireland Limited | Topical pharmaceutical compositions for treating skin conditions |
CA3133174A1 (en) | 2019-03-14 | 2020-09-17 | Crescita Therapeutics Inc. | Rinse-off compositions and uses thereof for delivery of active agents |
US20230057282A1 (en) * | 2020-02-11 | 2023-02-23 | Taro Pharmaceutical Industries Ltd. | Compositions comprising desoximetasone and tazarotene |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU75903A1 (es) | 1976-09-29 | 1978-05-16 | ||
NL7105591A (en) | 1971-04-24 | 1972-10-26 | Topical antiphlogistic compsns - contng 3, 20-diketo-9 alpha, 11 beta-dichloro - 16 alpha, 17 alpha-dimethyl-21-hydroxy pregna-1,4- | |
DE2655570A1 (de) | 1975-12-12 | 1977-06-16 | Ciba Geigy Ag | Neue polyhalogensteroide und verfahren zu ihrer herstellung |
US4048310A (en) | 1976-02-24 | 1977-09-13 | E. R. Squibb & Sons, Inc. | Topical steroid formulation in form of lotion or cream |
US4083974A (en) | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
JPS5850964B2 (ja) * | 1978-03-07 | 1983-11-14 | 東興薬品工業株式会社 | ステロイド含有クリ−ム製剤およびその製造方法 |
US4233295A (en) | 1979-05-31 | 1980-11-11 | E. R. Squibb & Sons, Inc. | Corticosteroid formulations containing sebacate carrier |
AU5794680A (en) | 1979-05-31 | 1980-12-04 | E.R. Squibb & Sons, Inc. | Corticosteroid stick formulations |
US4299828A (en) * | 1979-05-31 | 1981-11-10 | E. R. Squibb & Sons, Inc. | Corticosteroid stick formulations |
CH649923A5 (de) * | 1980-10-06 | 1985-06-28 | Glaxo Group Ltd | Topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide. |
JPS58225009A (ja) | 1982-06-23 | 1983-12-27 | Shionogi & Co Ltd | コルチコステロイド外用製剤 |
DE3225848A1 (de) | 1982-07-07 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Kortikoidhaltige zubereitung zur topischen applikation |
US4552872A (en) | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
GB8401965D0 (en) | 1984-01-25 | 1984-02-29 | Beecham Group Plc | Composition |
JPH0764734B2 (ja) * | 1986-03-17 | 1995-07-12 | 大正製薬株式会社 | 経皮投与製剤 |
CA1303991C (en) | 1986-03-31 | 1992-06-23 | Chung H. Cheng | Composition and method for delivering a steroid active ingredient |
JPS62238216A (ja) * | 1986-04-03 | 1987-10-19 | Otsuka Pharmaceut Factory Inc | ステロイドクリ−ム製剤 |
US5019569A (en) | 1986-11-03 | 1991-05-28 | Ortho Pharmaceutical Corporation | Reversal of glucocorticoid-induced skin atrophy |
JPH0676327B2 (ja) | 1987-04-14 | 1994-09-28 | 株式会社大塚製薬工場 | ステロイド軟膏製剤 |
JPH0676328B2 (ja) * | 1987-04-14 | 1994-09-28 | 株式会社大塚製薬工場 | ステロイドクリ−ム製剤 |
JPH07116026B2 (ja) | 1987-07-07 | 1995-12-13 | 株式会社資生堂 | ジクロフェナックナトリウム含有乳化外用剤 |
US5422361A (en) * | 1989-12-20 | 1995-06-06 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
CA2051621C (en) | 1990-03-02 | 2001-06-05 | Shiseido Company, Ltd. | Oil-in-water type emulsified composition comprising non-steroidal antiphlogistic and analgesic drug |
US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
TW218849B (es) * | 1991-05-17 | 1994-01-11 | Bristol Myers Squibb Co | |
WO1993009583A1 (en) * | 1991-10-29 | 1993-05-13 | Audio Authority Corporation | Apparatus and method for interconnecting electronic products |
WO1998036753A1 (en) | 1997-02-20 | 1998-08-27 | Allergan Sales,Inc. | Tazarotene and corticosteroid treatment for psoriasis |
US5972920A (en) * | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
SE9800729L (sv) | 1998-03-06 | 1999-09-07 | Scotia Lipidteknik Ab | Ny topikal formulering I |
US5990100A (en) * | 1998-03-24 | 1999-11-23 | Panda Pharmaceuticals, L.L.C. | Composition and method for treatment of psoriasis |
GB9823036D0 (en) * | 1998-10-22 | 1998-12-16 | Glaxo Group Ltd | Fluticasone lotion having improved vasoconstrictor activity |
AU1803100A (en) * | 1999-01-06 | 2000-07-24 | Taisho Pharmaceutical Co., Ltd. | Amelometasone lotion |
WO2000047211A1 (en) | 1999-02-12 | 2000-08-17 | Susan Bershad | Short contact treatment of psoriasis with topical retinoids |
ATE273682T1 (de) | 1999-06-25 | 2004-09-15 | Durham Pharmaceuticals Ltd | Topische formulierungen, die hautpenetrations- mittel enthalten, und ihre verwendung |
US6656928B1 (en) * | 1999-09-02 | 2003-12-02 | Mccadden Michael E. | Composition for the topical treatment of rashes, dermatoses and lesions |
US6479058B1 (en) | 1999-09-02 | 2002-11-12 | Mccadden Michael E. | Composition for the topical treatment of poison ivy and other forms of contact dermatitis |
US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
US6579512B2 (en) * | 2001-06-15 | 2003-06-17 | Crutchfield, Iii Charles E. | Topical steroid spray |
US6709663B2 (en) | 2001-08-31 | 2004-03-23 | Healthpoint, Ltd. | Multivesicular emulsion drug delivery systems |
US6765001B2 (en) | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
MXPA04006000A (es) * | 2001-12-21 | 2004-09-27 | Rhodia | Composiciones de tensioactivo cationico y anionico estables combinadas. |
US7544674B2 (en) | 2002-10-25 | 2009-06-09 | Galderma S.A. | Topical skin care composition |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20060018937A1 (en) | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
JP2004359585A (ja) | 2003-06-03 | 2004-12-24 | Medorekkusu:Kk | 被膜形成型の副腎皮質ステロイド薬含有外用製剤 |
US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US8741333B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
US8449867B2 (en) * | 2004-08-31 | 2013-05-28 | Stiefel Research Australia Pty Ltd | Microemulsion and sub-micron emulsion process and compositions |
CA2601123A1 (en) | 2005-03-15 | 2006-09-21 | Kyowa Hakko Kogyo Co., Ltd. | External preparation |
CA2607434A1 (en) | 2005-04-25 | 2006-11-02 | Dow Pharmaceutical Sciences | Use of a clobetasol spray formulation to treat psoriasis |
WO2007070423A2 (en) | 2005-12-09 | 2007-06-21 | Nycomed Us Inc. | Topical glucocorticosteroid formulations |
EP1968541A2 (en) | 2005-12-14 | 2008-09-17 | Zars, Inc. | Compositions and methods for dermal delivery of drugs |
ES2530390T3 (es) | 2006-07-05 | 2015-03-02 | Foamix Pharmaceuticals Ltd | Vehículo espumante de ácido carboxílico y composiciones farmacéuticas del mismo |
AU2007355106A1 (en) | 2006-11-29 | 2008-12-18 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
US20100323998A1 (en) * | 2007-08-06 | 2010-12-23 | Glenmark Pharmaceuticals Ltd. | Topical composition containing the combination of mupirocin and beclomethasone |
RU2470645C2 (ru) | 2007-09-10 | 2012-12-27 | Гленмарк Фармасьютикалс Лимитед | Фармацевтическая композиция для местного применения, содержащая комбинацию фузидовой кислоты и кортикостероида |
WO2009084020A2 (en) | 2007-10-18 | 2009-07-09 | Glenmark Pharmaceuticals Limited | Topical composition comprising halobetasol and salicylic acid |
KR102080429B1 (ko) | 2008-06-26 | 2020-02-21 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
AU2009300331A1 (en) * | 2008-10-03 | 2010-04-08 | Nexmed Holdings, Inc. | Stabilized composition for treating psoriasis |
US20100249060A1 (en) * | 2009-02-23 | 2010-09-30 | Smith Jan G | Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes |
AU2010217190B2 (en) | 2009-02-25 | 2012-10-25 | Mayne Pharma Llc | Topical foam composition |
US20130310355A1 (en) | 2009-12-15 | 2013-11-21 | Young Pharmaceuticals, Inc. | Low toxicity topical active agent delivery system |
US9782341B2 (en) | 2010-10-15 | 2017-10-10 | John E. Kulesza | Delivery of hydrophobic bioactive agents |
US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
US8809307B2 (en) | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
US8962028B2 (en) | 2012-10-18 | 2015-02-24 | MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company | Topical steroid composition and method |
-
2011
- 2011-11-02 US US13/287,176 patent/US8809307B2/en active Active
- 2011-11-09 MX MX2013005764A patent/MX346961B/es active IP Right Grant
- 2011-11-09 KR KR1020187002956A patent/KR101967121B1/ko active IP Right Grant
- 2011-11-09 PT PT118504190T patent/PT2643002T/pt unknown
- 2011-11-09 SI SI201132078T patent/SI2643002T1/sl unknown
- 2011-11-09 ES ES11850419T patent/ES2935814T3/es active Active
- 2011-11-09 RU RU2013128607/15A patent/RU2568598C2/ru active
- 2011-11-09 CN CN201180056051.0A patent/CN103228281B/zh active Active
- 2011-11-09 BR BR112013012476-8A patent/BR112013012476B1/pt active IP Right Grant
- 2011-11-09 CA CA2817524A patent/CA2817524C/en active Active
- 2011-11-09 WO PCT/US2011/059861 patent/WO2012087443A1/en active Application Filing
- 2011-11-09 LT LTEPPCT/US2011/059861T patent/LT2643002T/lt unknown
- 2011-11-09 NZ NZ610659A patent/NZ610659A/en unknown
- 2011-11-09 EP EP11850419.0A patent/EP2643002B1/en active Active
- 2011-11-09 PL PL11850419.0T patent/PL2643002T3/pl unknown
- 2011-11-09 CA CA3055328A patent/CA3055328C/en active Active
- 2011-11-09 KR KR1020137016271A patent/KR20140043044A/ko active Search and Examination
- 2011-11-09 HR HRP20230032TT patent/HRP20230032T1/hr unknown
- 2011-11-09 EP EP22215648.1A patent/EP4233838A3/en active Pending
- 2011-11-09 JP JP2013539894A patent/JP6111007B2/ja active Active
- 2011-11-09 AU AU2011345240A patent/AU2011345240B2/en active Active
- 2011-11-09 HU HUE11850419A patent/HUE061270T2/hu unknown
-
2013
- 2013-05-16 IL IL226398A patent/IL226398B2/en unknown
-
2014
- 2014-07-24 US US14/340,367 patent/US11213587B2/en active Active
-
2017
- 2017-06-06 US US15/615,752 patent/US10478502B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX346961B (es) | Formulaciones farmaceuticas que contienen corticosteroides para la administracion topica. | |
MX340591B (es) | Formulaciones de liberacion inmediata y formas de dosis de gamma-hidroxibutirato. | |
EP4342546A3 (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
MX2016013693A (es) | Crema transdermica. | |
MY188598A (en) | Dexmedetomidine premix formulation | |
MX2013010471A (es) | Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan. | |
PH12014502778B1 (en) | Antibody formulation | |
MX2019007956A (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
MX2014008284A (es) | Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta. | |
JO3071B1 (ar) | تركيبة مُعقدة تعطى بالفم مشتملة على إيستر أحماض دهنية أوميغا 3 ومُثبط مختزل هيدروكسي مثيل جلوتاريل ــ ملونات | |
MX351584B (es) | Formulacion farmaceutica acuosa de tapentadol para administracion oral. | |
MX352328B (es) | Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. | |
MX2014008283A (es) | Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta. | |
EP2823819A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING OLEANOLIC ACID ACETATE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF MEDIATED DISEASE BY TLR OR IL-6 | |
BR112013020167A2 (pt) | melhoradores de permeação para formulações tópicas | |
NZ718163A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
NZ702342A (en) | Pharmaceutical formulation | |
MX2009009838A (es) | Esteres de acidos grasos de glucocorticoides como agentes antiinflamatorios y anti-cancer. | |
IN2014CN03214A (es) | ||
MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
MX2014001065A (es) | Formulaciones de (trimetoxifenilamino) pirimidilino nuevas. | |
IN2014MN02156A (es) | ||
MX2015010594A (es) | Esteres de testosterona de cadena larga lipobalanceados para suministro oral. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |